Product news

Share this article:
Barr Pharmaceuticals said its subsidiary Barr Laboratories received FDA approval for its application to manufacture and market a generic version of Pharmacia and Upjohn's Dostinex (cabergoline) tablets, 0.5 mg. The company’s Abbreviated New Drug Application was acquired from Teva Pharmaceutical Industries in connection with the acquisition of Ivax by Teva in January 2006. Barr plans to launch a product that is supplied by Teva in September 2007. Dostinex had annual sales of approximately $68 million for the twelve months ended May 2007. Cabergoline tablets are used in the treatment of certain hormone problems related to milk production and may also be used for prolactin-producing tumors and to adjust hormone levels.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters